Three reasons this is down:
1)Edgemont Pharma is a small company without many drugs in the market. They are still a big question mark.
2) Look at the MD on Edgemont's staff, "Dr. Robert L. Zerbe, MD" Shares the same last name as the CEO of IGXT. I am not sure if this is coincidence.
3) I agree that this is still a win for IGXT, but this proves that this drug will not take IGXT to stardom alone, we must be patient and wait for the remainder of their pipeline before things take off.